Cas:25293-64-5 bis(oxiran-2-ylmethyl) 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate manufacturer & supplier

Chemical Name:bis(oxiran-2-ylmethyl) 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate

CAS.NO:25293-64-5

Synonyms:4,5-Epoxycyclohexane-1,2-dicarboxylic acid diglycidyl ester;Diglycidyl 4,5-epoxycyclohexane-1,2-dicarboxylate

Molecular Formula:C₁₄H₁₈O₇

Molecular Weight:298.28900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:447.4ºC at 760 mmHg

Density:1.406

Index of Refraction:1.543

PSA:90.19000

Exact Mass:298.10500

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4,5-Epoxycyclohexane-1,2-dicarboxylic acid diglycidyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Diglycidyl 4,5-epoxycyclohexane-1,2-dicarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Diglycidyl 4,5-epoxycyclohexane-1,2-dicarboxylate Use and application,4,5-Epoxycyclohexane-1,2-dicarboxylic acid diglycidyl ester technical grade,usp/ep/jp grade.

Related News: Safety concerns about the J&J vaccine paired with flagging U.S. demand for vaccinations in general have slowed rollout of the one-shot vaccine to a crawl. Close to half of the 21 million doses produced for the United States sit unused. bis(oxiran-2-ylmethyl) 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate manufacturer The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). bis(oxiran-2-ylmethyl) 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate supplier If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such. bis(oxiran-2-ylmethyl) 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate vendor The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). bis(oxiran-2-ylmethyl) 7-oxabicyclo[4.1.0]heptane-3,4-dicarboxylate factory With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.